Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer

Nature Medicine

Volumn 22, Issue 3, 2016, Pages 298-305

  Beltran, Himisha ^a,b   Prandi, Davide ^c   Mosquera, Juan Miguel ^a,b   Benelli, Matteo ^c   Puca, Loredana ^a   Cyrta, Joanna ^a   Marotz, Clarisse ^a   Giannopoulou, Eugenia ^b   Chakravarthi, Balabhadrapatruni V S K ^d   Varambally, Sooryanarayana ^d   Tomlins, Scott A ^e   Nanus, David M ^b   Tagawa, Scott T ^b   Van Allen, Eliezer M ^f,g   Elemento, Olivier ^a,b   Sboner, Andrea ^a,b   Garraway, Levi A ^f,g,h   Rubin, Mark A ^a,b   Demichelis, Francesca ^a,b,c  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF TRENTO   (Italy)

^d University of Alabama at Birmingham   (United States)

^e UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^f DANA FARBER CANCER INSTITUTE   (United States)

^g HARVARD UNIVERSITY   (United States)

^h BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; BRCA2 PROTEIN; DNA; MESSENGER RNA; PROTEIN MYB; PROTEIN P53; RETINOBLASTOMA PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; CANCER RESISTANCE; CASTRATION RESISTANT NEUROENDOCRINE PROSTATE CANCER; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL FEATURE; CLONAL EVOLUTION; CLONAL VARIATION; COPY NUMBER VARIATION; DNA METHYLATION; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MISMATCH REPAIR; PANCREATIC NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; PROSTATE CANCER CELL LINE; RNA EXTRACTION; TUMOR BIOPSY; ADENOCARCINOMA; AGED; BONE TUMOR; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; LIVER TUMOR; MIDDLE AGED; NEUROENDOCRINE TUMOR; PATHOLOGY; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SECONDARY; VERY ELDERLY;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; CLONAL EVOLUTION; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RECEPTORS, ANDROGEN; RETROSPECTIVE STUDIES;

EID: 84957623685     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.4045     Document Type: Article

References (68)

1. Siegel, R.L., Miller, K.D. & Jemal, A. Cancer statistics, 2015. CA Cancer J. Clin. 65, 5-29 (2015).
2. Huggins, C. & Hodges, C.V. Studies on prostatic cancer: I. the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J. Urol. 168, 9-12 (2002).
3. Chen, C.D. et al. Molecular determinants of resistance to antiandrogen therapy. Nat. Med. 10, 33-39 (2004).
4. Knudsen, K.E. & Scher, H.I. Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer. Clin. Cancer Res. 15, 4792-4798 (2009).
5. Scher, H.I. et al.; AFFIRM Investigators. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 367, 1187-1197 (2012).
6. de Bono, J.S. et al.; COU-AA-301 Investigators. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364, 1995-2005 (2011).
7. Watson, P.A. et al. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat. Rev. Cancer 15, 701-711 (2015).
8. Epstein, J.I. et al. Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Am. J. Surg. Pathol. 38, 756-767 (2014).
9. Beltran, H. et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov. 1, 487-495 (2011).
10. Yao, J.L. et al. Small-cell carcinoma of the prostate: an immunohistochemical study. Am. J. Surg. Pathol. 30, 705-712 (2006).
11. Beltran, H. et al. Challenges in recognizing treatment-related neuroendocrine prostate cancer. J. Clin. Oncol. 30, e386-e389 (2012).
12. Aparicio, A. & Tzelepi, V. Neuroendocrine (small-cell) carcinomas: why they teach us essential lessons about prostate cancer. Oncology 28, 831-838 (2014).
13. Lin, D. et al. High-fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development. Cancer Res. 74, 1272-1283 (2014).
14. Wang, H.T. et al. Neuroendocrine prostate cancer (NEPC) progressing from conventional prostatic adenocarcinoma: factors associated with time to development of NEPC and survival from NEPC diagnosis-a systematic review and pooled analysis. J. Clin. Oncol. 32, 3383-3390 (2014).
15. Hieronymus, H. et al. Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell 10, 321-330 (2006).
16. Chen, H. et al. Pathogenesis of prostatic small-cell carcinoma involves the inactivation of the p53 pathway. Endocr. Relat. Cancer 19, 321-331 (2012).
17. Zhou, Z. et al. Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer. Cancer Res. 66, 7889-7898 (2006).
18. Tan, H.L. et al. Rb loss is characteristic of prostatic small-cell neuroendocrine carcinoma. Clin. Cancer Res. 20, 890-903 (2014).
19. Grasso, C.S. et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 487, 239-243 (2012).
20. Robinson, D. et al. Integrative clinical genomics of advanced prostate cancer. Cell 161, 1215-1228 (2015).
21. Hu, R. et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res. 69, 16-22 (2009).
22. Antonarakis, E. et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N. Engl. J. Med. 371, 1028-1038 (2014).
23. Baca, S.C. et al. Punctuated evolution of prostate cancer genomes. Cell 153, 666-677 (2013).
24. Barbieri, C.E. et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat. Genet. 44, 685-689 (2012).
25. Pritchard, C.C. et al. Complex MSH2 and MSH6 mutations in hypermutated microsatellite-unstable advanced prostate cancer. Nat. Commun. 25, 4988 (2014).
26. Prandi, D. et al. Unraveling the clonal hierarchy of somatic genomic aberrations. Genome Biol. 15, 439 (2014).
27. Forbes, S.A. et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res. 43, D805-D811 (2015).
28. Rajan, N. et al. The cylindromatosis gene product, CYLD, interacts with MIB2 to regulate Notch signaling. Oncotarget 5, 12126-12140 (2014).
29. Lim, J.H. et al. CYLD negatively regulates transforming growth factor-β-signaling via deubiquitinating Akt. Nat. Commun. 3, 771 (2012).
30. Theurillat, J.P. et al. Prostate cancer. Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer. Science 346, 85-89 (2014).
31. Lin, L. et al. Mechanisms underlying cancer growth and apoptosis by DEK overexpression in colorectal cancer. PLoS One 9, e111260 (2014).
32. Nowell, P.C. The clonal evolution of tumor cell populations. Science 194, 23-28 (1976).
33. Maley, C.C. et al. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat. Genet. 38, 468-473 (2006).
34. Hansel, D.E. et al. Shared TP53 gene mutation in morphologically and phenotypically distinct concurrent primary small-cell neuroendocrine carcinoma and adenocarcinoma of the prostate. Prostate 69, 603-609 (2009).
35. Gundem, G. et al. The evolutionary history of lethal metastatic prostate cancer. Nature 520, 353-357 (2015).
36. Smith, B.A. et al. A basal stem cell signature identifies aggressive prostate cancer phenotypes. Proc. Natl. Acad. Sci. USA 112, E6544-E6552 (2015).
37. Steffan, J.J. et al. The transcription factor SPDEF suppresses prostate tumor metastasis. J. Biol. Chem. 287, 29968-29978 (2012).
38. Börno, S.T. et al. Genome-wide DNA methylation events in TMPRSS2-ERG fusion-negative prostate cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylation. Cancer Discov. 2, 1024-1035 (2012).
39. Varambally, S. et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 322, 1695-1699 (2008).
40. Yu, J. et al. A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res. 67, 10657-10663 (2007).
41. Karanikolas, B.D., Figueiredo, M.L. & Wu, L. Comprehensive evaluation of the role of EZH2 in the growth, invasion and aggression of a panel of prostate cancer cell lines. Prostate 70, 675-688 (2010).
42. Clermont, P.L. et al. Polycomb-mediated silencing in neuroendocrine prostate cancer. Clin. Epigenetics 7, 40 (2015).
43. Cheng, A.S. et al. EZH2-mediated concordant repression of Wnt antagonists promotes β-catenin-dependent hepatocarcinogenesis. Cancer Res. 71, 4028-4039 (2011).
44. Kanduri, M. et al. A key role for EZH2 in epigenetic silencing of HOX genes in mantle-cell lymphoma. Epigenetics 8, 1280-1288 (2013).
45. Akamatsu, S. et al. The placental gene PEG10 promotes progression of neuroendocrine prostate cancer. Cell Rep. 12, 922-936 (2015).
46. Cancer Genome Atlas Research Network. The molecular taxonomy of primary prostate cancer. Cell 163, 1011-1025 (2015).
47. Chakravarty, D. et al. The estrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer. Nat. Commun. 5, 5383 (2014).
48. Carreira, S. et al. Tumor clone dynamics in lethal prostate cancer. Sci. Transl. Med. 6, 254ra125 (2014).
49. Beltran, H. et al. Whole-exome sequencing of metastatic cancer and biomarkers of treatment response. JAMA Oncol. 1, 466-474 (2015).
50. Esgueva, R. et al. Next-generation prostate cancer biobanking: toward a processing protocol amenable for the International Cancer Genome Consortium. Diagn. Mol. Pathol. 21, 61-68 (2012).
51. Van Allen, E.M. et al. Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nat. Med. 20, 682-688 (2014).
52. Cibulskis, K. et al. ContEst: estimating cross-contamination of human samples in next-generation sequencing data. Bioinformatics 27, 2601-2602 (2011).
53. Demichelis, F. et al. SNP panel identification assay (SPIA): a genetic-based assay for the identification of cell lines. Nucleic Acids Res. 36, 2446-2456 (2008).
54. Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213-219 (2013).
55. Ramos, A.H. et al. Oncotator: cancer variant annotation tool. Hum. Mutat. 36, E2423-E2429 (2015).
56. Lawrence, M.S. et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499, 214-218 (2013).
57. Romanel, A., Lago, S., Prandi, D., Sboner, A. & Demichelis, F. ASEQ: fast allele-specific studies from next-generation sequencing data. BMC Med. Genomics 8, 9 (2015).
58. Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15-21 (2013).
59. Habegger, L. et al. RSEQtools: a modular framework to analyze RNA-seq data using compact, anonymized data summaries. Bioinformatics 27, 281-283 (2011).
60. Park, K. et al. Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia 12, 590-598 (2010).
61. Sboner, A. et al. FusionSeq: a modular framework for finding gene fusions by analyzing paired-end RNA-sequencing data. Genome Biol. 11, R104 (2010).
62. Mosquera, J.M. et al. Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. Neoplasia 15, 1-10 (2013).
63. Lin, P.C. et al. Epigenomic alterations in localized and advanced prostate cancer. Neoplasia 15, 373-383 (2013).
64. Akalin, A. et al. methylKit: a comprehensive R package for the analysis of genome-wide DNA methylation profiles. Genome Biol. 13, R87 (2012).
65. Dale, R.K., Pedersen, B.S. & Quinlan, A.R. Pybedtools: a flexible Python library for manipulating genomic datasets and annotations. Bioinformatics 27, 3423-3424 (2011).
66. Chen, J., Bardes, E.E., Aronow, B.J. & Jegga, A.G. ToppGene Suite for gene list enrichment analysis and candidate gene prioritization. Nucleic Acids Res. 37, W305-W311 (2009).
67. Viré, E. et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 439, 871-874 (2006).
68. Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401-404 (2012).